Evidence for Benefits of Early Treatment Initiation for Chronic Hepatitis B
Evidence for Benefits of Early Treatment Initiation for Chronic Hepatitis B
About this item
Full title
Author / Creator
Publisher
Switzerland: MDPI AG
Journal title
Language
English
Formats
Publication information
Publisher
Switzerland: MDPI AG
Subjects
More information
Scope and Contents
Contents
Chronic hepatitis B (CHB) is the most common cause of hepatocellular carcinoma (HCC) worldwide. Antiviral treatment reduces the risk of HCC and mortality; nonetheless, globally in 2019, only 2.2% of CHB patients received treatment. Current international CHB guidelines recommend antiviral treatment only in subsets of patients with clear evidence of...
Alternative Titles
Full title
Evidence for Benefits of Early Treatment Initiation for Chronic Hepatitis B
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_b0f820d04b534e6eae9f1231aec2919b
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_b0f820d04b534e6eae9f1231aec2919b
Other Identifiers
ISSN
1999-4915
E-ISSN
1999-4915
DOI
10.3390/v15040997
